{
  "ticker": "CTMX",
  "company_name": "CytomX Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03993379",
      "title": "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Solid Tumor, Unresectable or Metastatic Melanoma",
      "start_date": "2019-11-20",
      "completion_date": "2020-05-21",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT04596150",
      "title": "Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative",
      "start_date": "2020-12-29",
      "completion_date": "2023-06-02",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT03149549",
      "title": "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer",
      "start_date": "2017-06-01",
      "completion_date": "2020-09-10",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT06265688",
      "title": "First In Human Study of CX-2051 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult",
      "start_date": "2024-04-02",
      "completion_date": "2029-03-31",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT03706274",
      "title": "PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult",
      "start_date": "2020-01",
      "completion_date": "2022-12",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT05387265",
      "title": "A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Solid Tumors",
      "start_date": "2022-05-16",
      "completion_date": "2025-06-04",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT06462794",
      "title": "First In Human Study of CX-801 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult",
      "start_date": "2024-08-28",
      "completion_date": "2029-06-30",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT03013491",
      "title": "PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumor, Lymphoma",
      "start_date": "2017-01-19",
      "completion_date": "2020-10-27",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    },
    {
      "nct_id": "NCT03543813",
      "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer",
      "start_date": "2018-06-15",
      "completion_date": "2023-06-01",
      "enrollment": 0,
      "sponsor": "CytomX Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 9,
    "by_phase": {
      "PHASE2": 2,
      "PHASE1, PHASE2": 3,
      "PHASE1": 4
    },
    "by_status": {
      "TERMINATED": 4,
      "COMPLETED": 2,
      "RECRUITING": 2,
      "WITHDRAWN": 1
    },
    "active_trials": 2,
    "completed_trials": 2,
    "conditions": [
      "Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative",
      "Solid Tumor, Adult",
      "Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer",
      "Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer",
      "Solid Tumor, Lymphoma",
      "Solid Tumor, Unresectable or Metastatic Melanoma",
      "Solid Tumors"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:49.665895",
    "search_query": "CytomX Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=CytomX+Therapeutics,+Inc."
  }
}